Dr. Kreider is a Principal Health Scientist with Cardno ChemRisk where she serves primarily as a toxicologist. With nearly 15 years of consulting experience, she has had the opportunity to manage a variety of projects, including reviewing of toxicological literature for a variety of chemical types (including materials in tire manufacture, VOCs, automobile exhausts, perfluorinated chemicals, and particulate matter, etc.); designing, managing and interpreting toxicity studies; conducting or critiquing dose response assessments for chemicals or particulate; supporting corporate product stewardship initiatives; assisting with regulatory needs around a variety of chemicals management regulations (TSCA, REACH, Prop 65, etc.) and conducting quantitative or qualitative risk assessments on chemicals and/or consumer products. Dr. Kreider has an expertise in product stewardship, and has assisted a variety of clients in understanding human health and environmental impacts associated with products at various life cycle stages. Dr. Kreider received her Ph.D. from the Department of Pharmacology and Cancer Biology at Duke University, where her thesis evaluated the developmental neurotoxicity of pharmacotherapies used in the treatment of preterm labor.
- PhD, Duke University, May 2005
- BS, University of Pittsburgh, April 2001
- Society of Toxicology (SOT) - Student member, 2002 - 2006; Full member, 2011 – current; Neurotoxicology Specialty Section, 2002 - 2006; Risk Assessment Specialty Section, 2011 – current; Nanotoxicology Specialty Section, 2011 – current; Allegheny-Erie Society of Toxicology, 2011 – current; President-Elect 2018-2019; current acting President
- American Industrial Hygiene Association (AIHA); Member, 2014-present
- Society for Environmental Toxicology and Chemistry (SETAC); Member, 2014
- Diplomate of the American Board of Toxicology (2013-current)
Most Recent Awards/Professional Honors
- Awarded 2014 Best Published Paper Regarding Medical Devices for Toxicology-based cancer causation analysis of CoCr-containing hip implants: a quantitative assessment of genotoxicity and tumorigenicity studies (J Appl Tox. 34(9):939-967). Medical Device and Combination Product Specialty Section – Society of Toxicology Annual Meeting, San Diego, CA, March 2015.